TY  - JOUR
AU  - Pérez-Mato, María
AU  - Iglesias-Rey, Ramón
AU  - Vieites-Prado, Alba
AU  - Dopico-López, Antonio
AU  - Argibay, Bárbara
AU  - Fernández-Susavila, Héctor
AU  - da Silva-Candal, Andrés
AU  - Pérez-Díaz, Amparo
AU  - Correa-Paz, Clara
AU  - Günther, Anne
AU  - Ávila-Gómez, Paulo
AU  - Isabel Loza, M.
AU  - Baumann, A.
AU  - Castillo, José
AU  - Sobrino, Tomás
AU  - Campos, Francisco
TI  - Blood glutamate EAAT2-cell grabbing therapy in cerebral ischemia
JO  - EBioMedicine
VL  - 39
SN  - 2352-3964
CY  - Amsterdam [u.a.]
PB  - Elsevier
M1  - FZJ-2019-00769
SP  - 118-131
PY  - 2019
AB  - BackgroundExcitatory amino acid transporter 2 (EAAT2) plays a pivotal role in glutamate clearance in the adult brain, thereby preventing excitotoxic effects. Considering the high efficacy of EAAT2 for glutamate uptake, we hypothesized that the expression of this transporter in mesenchymal stem cells (MSCs) for systemic administration could yield a cell-based glutamate-grabbing therapy, combining the intrinsic properties of these cells with excitotoxic protection.MethodsTo address this hypothesis, EAAT2-encoding cDNA was introduced into MSCs and human embryonic kidney 293 cells (HEK cells) as the control cell line. EAAT2 expression and functionality were evaluated by in vitro assays. Blood glutamate-grabbing activity was tested in healthy and ischemic rat models treated with 3 × 106 and 9 × 106 cells/animal.FindingsThe expression of EAAT2 in both cell types conferred the expected glutamate-grabbing activity in in vitro and in vivo studies. The functional improvement observed in ischemic rats treated with EAAT2–HEK at low dose, confirmed that this effect was indeed mediated by the glutamate-grabbing activity associated with EAAT2 functionality. Unexpectedly, both cell doses of non-transfected MSCs induced higher protection than transfected EAAT2–MSCs by another mechanism independent of the glutamate-grabbing capacity.InterpretationAlthough the transfection procedure most likely interferes with some of the intrinsic protective mechanisms of mesenchymal cells, the results show that the induced expression of EAAT2 in cells represents a novel alternative to mitigate the excitotoxic effects of glutamate and paves the way to combine this strategy with current cell therapies for cerebral ischemia.
LB  - PUB:(DE-HGF)16
C6  - pmid:30555045
UR  - <Go to ISI:>//WOS:000456677400024
DO  - DOI:10.1016/j.ebiom.2018.11.024
UR  - https://juser.fz-juelich.de/record/859963
ER  -